ClinicalTrials.gg
CompletedNCT06352658Updated Jan 30, 2025

Efficacy of Different Treatments for Obstructive Sleep Apnea

An interventional study of Conventional mandibular advancement device and CAD CAM mandibular advancement device in Apnea, sponsored by Nourhan M.Aly. Completed at 1 site in Egypt. Open to participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by Nourhan M.Aly · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Feb 2023, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
All
01

Study summary

This was a prospective randomized controlled clinical trial that aimed to evaluate the efficacy of three treatments for obstructive sleep Apnea OSA:

  1. Conventionally constructed mandibular advancement device (MAD).
  2. Digitally constructed mandibular advancement device (CAD CAM).
  3. Uvulopalatopharyngeoplasty (UPPP).
02

Conditions studied

  • Apnea

Browse trials for

03

In context

Apnea

283 studies on the registry are indexed under Apnea; 55 are open to participants now.

This study's enrollment of 45 is below the median of 60 across 196 interventional studies indexed under Apnea.

Browse Apnea studies →

Lead sponsor

Nourhan M.Aly is the lead sponsor of 49 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adequate nasal air flow capacity as determined by qualified otolaryngologist
  • Cases showing improvement in airway with mandibular advancement on Acoustic Pharyngometry (AP)
  • Patients with the minimum component of dentition to support MDSA.
  • Patients with the mandibular protrusive movement of more than 5 mm
  • (BMI) less than 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Severe nasal passage obstructions or allergies
  • Obesity ( greater than 30 kg/m2 )
  • Cases with Mallampati score greater than Class 1
  • Systemic complications, syndrome, or disease affecting airway
  • Severe periodontal disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Active comparator
    Conventional mandibular advancement device

    Device: Conventional mandibular advancement device

  • Experimental
    CAD CAM mandibular advancement device

    Device: CAD CAM mandibular advancement device

  • Experimental
    Uvuloplatopharyngeoplasty UPPP

    Procedure: Uvuloplatopharyngeoplasty UPPP

Interventions

  • DeviceConventional mandibular advancement device

    With a vacuum mahine (Biostar, NY) a 2-mm-thick hard, clear resin sheet was adapted to the cast. The excess material was cut, borders were trimmed and smoothed. Maxillary mandibular casts were mounted by a protrusive the interocclusal record. The appliances were re-placed on the mounted casts to be splinted to form a Monoblock MAD by autopolymerizing acrylic resin at the premolar -molar area.

  • DeviceCAD CAM mandibular advancement device

    3D models for the stone casts were constructed with laser scanning machine (accuracy \<20 µm; D500, 3shape). Maxillary and mandibular casts were rescanned in the achieved 75% advancement position and monoblock device was designed by CAD (computer-aided design) with 3D software (3-matic; Materialise) and printed by

  • ProcedureUvuloplatopharyngeoplasty UPPP

    uvulopalatopharyngeoplasty UPPP were performed by the same ENT surgeon under GA.

06

What researchers measure

Primary outcomes

  1. Apnea hypopnea index

    The AHI measures an average number of apnea and hypopnea episodes that you experience per hour. According to the American Academy of Sleep Medicine (AASM) it is categorized into mild (5-15 events/hour), moderate (15-30 events/hr), and severe (\> 30 events/hr)

    Time frame: 4 months

  2. Epwoth sleeplness scale (ESS)

    The ESS is a subjective measure of a patient's sleepiness. The test is a list of eight situations in which the patien rates their tendency to become sleepy on a scale of 0, no chance of dozing, to 3, high chance of dozing. All scores on the ESS fall between 0 and 24. Scores from 0 to 10 reflect normal levels of daytime sleepiness, and scores over 10 are considered to reflect excessive daytime sleepiness.

    Time frame: 4 months

  3. Oxygen saturation

    This will be measured using an oximeter. A normal level of oxygen is usually 95% or higher.

    Time frame: 4 months

  4. Snoring index

    Snoring index measures the total number of snores per hour of sleep. This is calculated by dividing your total sleeping time by your snoring frequency. The normal range depends on the person's gender and the stage of sleep

    Time frame: 4 months

07

Study locations

1 site
  • Faculty of Dentistry, Alexandria University, Egypt
    Alexandria, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jan 2024, 11 months.

Of 69 non-industry interventional studies with no phase under Apnea, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 11 months is below that.

Counting every sponsor, half of 78 studies reached it within 17 months; a quarter within 8 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 8, 2024
StartActual
Feb 1, 2023
Primary completionActual
Jan 1, 2024
CompletionActual
Jan 10, 2024
Last update
Jan 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06352658
Lead sponsor
Nourhan M.Aly
Responsible party
Nourhan M.Aly (Assistant Lecturer of Dental Public Health, University of Alexandria) — Sponsor-investigator
First posted
Apr 8, 2024
Start date
Feb 1, 2023
Primary completion
Jan 1, 2024
Completion
Jan 10, 2024
Last update
Jan 30, 2025

Study contacts

Mona Sabry, PhD
principal investigator · Faculty of Dentistry, Alexandria University, Egypt

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion